RT Journal Article
SR Electronic
T1 A spatial model to optimise predictions of COVID-19 incidence risk in Belgium using symptoms as reported in a large-scale online survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.18.20105627
DO 10.1101/2020.05.18.20105627
A1 Neyens, Thomas
A1 Faes, Christel
A1 Vranckx, Maren
A1 Pepermans, Koen
A1 Hens, Niel
A1 Van Damme, Pierre
A1 Molenberghs, Geert
A1 Aerts, Jan
A1 Beutels, Philippe
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105627.abstract
AB Although COVID-19 has been spreading throughout Belgium since February, 2020, its spatial dynamics in Belgium remain poorly understood, due to the limited testing of suspected cases. We analyse data of COVID-19 symptoms, as self-reported in a weekly online survey, which is open to all Belgian citizens. We predict symptoms’ incidence using binomial models for spatially discrete data, and we introduce these as a covariate in the spatial analysis of COVID-19 incidence, as reported by the Belgian government during the days following a survey round. The symptoms’ incidence predictions explain a significant proportion of the variation in the relative risks based on the confirmed cases, and exceedance probability maps of the symptoms’ incidence and the confirmed cases’ relative risks pinpoint the same high-risk region. We conclude that these results can be used to develop public monitoring tools in scenarios with limited lab testing capacity, and to supplement test-based information otherwise.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received funding from the Flemish Government (AI Research Program). Authors NH and PB acknowledge funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of confirmed COVID-19 cases, as analysed in this study, are confidential. They are available in an aggregated format on https://epistat.wiv-isp.be/covid/. The data of COVID-19 symptoms that were reported by participants of the Big Corona Study are confidential, but can be accessed after approval by the Big Corona Study steering committee.